STOCK TITAN

Harrow (HROW) CEO Mark Baum exercises 180,000 stock options in company

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Harrow, Inc.'s chief executive officer and director Mark L. Baum reported exercising stock options for 180,000 shares of common stock at $3.95 per share.

After this option exercise and the withholding of 79,994 shares to satisfy the exercise price and tax obligations, he directly owns 2,986,130 shares of Harrow common stock. The company notes that the share withholding did not involve any market sales or other market transactions.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BAUM MARK L

(Last) (First) (Middle)
C/O HARROW, INC.
1A BURTON HILLS BLVD., SUITE 200

(Street)
NASHVILLE TN 37215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/12/2025 M 180,000 A $3.95 3,066,124 D
Common Stock 12/12/2025 F 79,994 D $47.06 2,986,130 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)(1) $3.95 12/12/2025 M 180,000 (1) 04/01/2026 Common Stock 180,000 $0 0 D
Explanation of Responses:
1. Represents stock options granted to Mr. Baum on April 1, 2016 under the Issuer's 2007 Stock Incentive and Awards Plan, as amended. The stock options vested quarterly over a three-year period following the grant date. 79,994 shares were withheld to satisfy the exercise price and tax liability incident to the exercise of the stock option. Such withholding did not involve any market sales or other market transactions.
/s/ Mark L Baum 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Harrow (HROW) report for CEO Mark L. Baum?

Harrow reported that its CEO and director Mark L. Baum exercised stock options for 180,000 shares of Harrow common stock at an exercise price of $3.95 per share.

How many Harrow (HROW) shares does CEO Mark L. Baum own after this transaction?

Following the reported transactions, Mark L. Baum directly owns 2,986,130 shares of Harrow, Inc. common stock.

Were any Harrow (HROW) shares sold on the market in this insider transaction?

No. The filing states that 79,994 shares were withheld to cover the exercise price and tax liability and that this withholding did not involve any market sales or other market transactions.

What was the origin of the stock options exercised by Harrow (HROW)'s CEO?

The exercised stock options were granted to Mark L. Baum on April 1, 2016 under Harrow’s 2007 Stock Incentive and Awards Plan, as amended, and vested quarterly over three years.

What do the transaction codes M and F mean in the Harrow (HROW) Form 4?

In this filing, code M reflects the exercise of stock options for 180,000 shares, while code F reflects 79,994 shares withheld to satisfy the exercise price and tax obligations related to that option exercise.
Harrow Health Inc

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.66B
31.21M
15.72%
57.42%
13.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE